NCT00619801View on ClinicalTrials.gov

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin

PHASE3CompletedINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Allergic RhinitisChronic Urticaria
Interventions
DRUG

Levocetirizine

Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks

DRUG

Placebo

Placebo oral drops (5 drops) dosed twice a day for 2 weeks.

Trial Locations (28)

Unknown

Birmingham

Little Rock

Beverly Hills

Crescent City

Huntington Beach

Mission Viejo

San Diego

Wildomar

Denver

Pueblo

Savannah

Stockbridge

Normal

Overlook Park

Owensboro

Metarie

Baltimore

Omaha

Papillon

Oklahoma City

Medford

Portland

Barnwell

Charleston

Dallas

El Paso

New Braunfels

Richmond

Sponsors

Lead Sponsor

UCB Pharma
All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT00619801 - Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin | Biotech Hunter | Biotech Hunter